Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls

Asirvatham, Jaya Ruth; Falcone, M.; Kleer, Celina G.

doi:10.5858/arpa.2016-0238-ra

Cited by 19 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myoepithelial cell markers (p63, calponin, smooth muscle myosin IHC) may be useful in cases of florid apocrine atypia within a sclerosing lesion (AASL) to avoid misinterpretation as invasive carcinoma 42. Awareness that the myoepithelial cell layer may be attenuated or partly lost in benign apocrine lesions is also important to avoid over diagnosis of malignancy 43…”

Section: Utility Of Ihc In Stratifying Apocrine Lesions Of the Breastmentioning

confidence: 99%

Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast

D’Arcy

Quinn

2018

J Clin Pathol

View full text Add to dashboard Cite

Pure apocrine carcinoma of the breast is rare and has been defined by using a combination of morphologic (apocrine morphology in >90% of tumour cells) and immunohistochemical criteria (oestrogen receptor (ER) and progesterone receptor (PR) negative and androgen receptor (AR) positive). Recent advances in the molecular classification of breast tumours have uncovered a subset of breast tumours associated with high expression of androgen receptor mRNA including the so-called ‘luminal androgen receptor (LAR) tumours’ and ‘molecular apocrine tumours’ (MATs). Recognition of these tumour subsets has opened potential avenues for therapies exploiting the AR pathway in triple negative breast carcinoma (TNBC). In this second part of our two-part review, we focus on the definition of pure apocrine carcinoma, recent advances in understanding the molecular apocrine signature in breast carcinoma, its relationship to pure apocrine carcinoma defined at the level of light microscopy and immunohistochemistry (IHC) and the therapeutic implications of androgen expression in TNBC. We complete the article with a summary of the utility of IHC in stratifying apocrine lesions of the breast.

show abstract

Section: Utility Of Ihc In Stratifying Apocrine Lesions Of the Breastmentioning

confidence: 99%

Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast

D’Arcy

Quinn

2018

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…The most accepted definition is the presence of ducts filled with neoplastic apocrine cells 21. As with other forms of DCIS, nuclear grade may be low, intermediate or high.…”

Section: Apocrine Dcismentioning

confidence: 99%

Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast

D’Arcy¹,

Quinn

2018

J Clin Pathol

View full text Add to dashboard Cite

Apocrine morphology is a common phenomenon encountered in everyday breast pathology practice, and is defined as cuboidal or columnar cells exhibiting abundant eosinophilic granular cytoplasm, prominent apical granules, a low nuclear-cytoplasmic ratio, and round nuclei with pale chromatin and prominent nucleoli. Apocrine morphology is recognised in benign, atypical and malignant lesions of the breast. The morphology of apocrine atypia and non-high-grade apocrine ductal carcinoma in situ (DCIS) is less well defined due to the relative rarity of these lesions. In part 1 of this two-part review, we focus on the morphological characteristics of benign, atypical and in situ apocrine lesions of the breast, summarise the available data to date regarding distinction of atypical apocrine proliferations from non-high-grade apocrine DCIS and the biological significance of apocrine atypia, and provide practical guidance on handling these difficult lesions. Part 2 of this review will focus on the concept of pure apocrine carcinoma with emphasis on its definition and molecular data, including the current understanding of the molecular apocrine signature in breast carcinoma. We complete the review with a synopsis on the utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.

show abstract

“…Some breast lesions are associated with apocrine phenotype features, such as atypical apocrine adenosis (AAA), apocrine ductal carcinoma in situ (DCIS), and invasive carcinoma with apocrine features [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Breast Atypical Apocrine Adenosis: A Case Report and Literature Review

Khan

Alkistawi

Idaewor

et al. 2020

Cureus

View full text Add to dashboard Cite

Atypical apocrine adenosis (AAA) is a benign lesion of the breast that is identified more frequently today than in the past when it was considered a rare diagnosis and commonly misdiagnosed as other malignant lesions of the breast. AAA is defined as the presence of apocrine cytology in a recognisable lobular unit associated with sclerosing adenosis. We present a case of an incidental finding of AAA and discuss diagnostic challenges and their implications on clinical management.

show abstract

Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls

Cited by 19 publications

References 23 publications

Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast

Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast

Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast

Breast Atypical Apocrine Adenosis: A Case Report and Literature Review

Contact Info

Product

Resources

About